Key takeaways

• p53 is a tetrameric transcription factor encoded by TP53 on the short arm of chromosome 17, and functions as the central hub of the DNA damage response.
• Its domains divide the labour: transactivation at the N-terminus, sequence-specific DNA binding in the core, and tetramerisation plus regulatory control at the C-terminus.
• Under normal conditions p53 is held at low levels by MDM2, which both blocks its transactivation domain and marks it for proteasomal degradation.
• Stress signals break the p53–MDM2 interaction, chiefly through ATM- and ATR-mediated phosphorylation, allowing p53 to accumulate and activate transcription.
• Cell cycle arrest runs mainly through p21 (CDKN1A); apoptosis runs through BAX, PUMA and other BH3 family members.
• Most cancer-associated mutations are missense changes in the DNA-binding domain, so mutant p53 is expressed but cannot bind its response elements — and can additionally act dominant-negatively over remaining wild-type protein.
• Because mutant p53 often accumulates to high levels while being non-functional, protein abundance alone is a poor proxy for p53 activity.

Contents

• What is p53?
• Protein structure and domains
• The p53 signalling pathway
• Regulation by MDM2 and beyond
• p53 target genes
• Mutations and cancer
• Therapeutic approaches
• How p53 is measured
• Choosing a p53 pathway kit
• Frequently asked questions

p53 pathway ELISA kits

p53 is only interpretable alongside the proteins it controls and the protein that controls it. The panel below covers the hub, its principal negative regulator, and the effectors for arrest, DNA damage and apoptosis.

TP53

Human p53 / TP53 ELISA Kit

Sandwich ELISAHuman

Quantifies total p53 protein in lysates, serum and plasma — the starting point for pathway work.

View kit →

MDM2

Human MDM2 ELISA Kit

Sandwich ELISAHuman

The E3 ligase that keeps p53 low; measuring both reveals whether the brake or the hub has changed.

View kit →

p21

Human p21 / CDKN1A ELISA Kit

Sandwich ELISAHuman

The principal effector of p53-driven cell cycle arrest, and the best single readout of p53 transcriptional activity.

View kit →

PUMA

Human PUMA / BBC3 ELISA Kit

Sandwich ELISAHuman

BH3-only protein mediating p53-dependent apoptosis after irreparable damage.

View kit →

BAX

Human BAX ELISA Kit

Sandwich ELISAHuman

Pro-apoptotic effector that permeabilises the mitochondrial outer membrane downstream of p53.

View kit →

GADD45γ

Human GADD45γ ELISA Kit

Sandwich ELISAHuman

Growth arrest and DNA-damage-inducible protein linking p53 activation to repair and checkpoint control.

View kit →

What is p53?

p53 is a transcription factor that acts as the principal sensor and coordinator of cellular stress. Encoded by TP53 on the short arm of chromosome 17, it is held at low abundance in unstressed cells and accumulates rapidly when DNA is damaged. Once stabilised, it binds sequence-specific response elements across the genome and switches on programmes that arrest the cell cycle, promote DNA repair, trigger apoptosis or impose senescence.

The logic is that of a checkpoint rather than a switch. A cell with repairable damage is halted long enough to fix it; a cell with irreparable damage is removed. Losing that arbitration allows damaged cells to keep dividing and accumulating mutations, which is why TP53 is the most frequently mutated gene across human cancers and why it earned the description “guardian of the genome”.

Protein structure and domains

Each p53 monomer is 393 amino acids long, and four monomers assemble into the tetramer that constitutes the active protein. p53 is modular, and the modules map cleanly onto its functions.

• Transactivation domains I and II (TAD1, TAD2) at the N-terminus recruit transcriptional co-activators and the general transcription machinery. This is also the surface that MDM2 binds, which is precisely how MDM2 silences p53 — by occluding the region needed to activate transcription.
• Proline-rich domain (PRD) mediates protein-protein interactions and contributes to the apoptotic response.
• Central DNA-binding domain (DBD) is the most conserved region and recognises p53 response elements. It is also where the overwhelming majority of cancer-associated missense mutations fall, which is the single most important structural fact about p53 in oncology.
• Tetramerisation domain (TD), sometimes called the oligomerisation domain, drives assembly of the active tetramer. These are two names for the same region, not two separate domains — p53 binds DNA as a tetramer, and mutations that disrupt tetramerisation abolish activity even when the DNA-binding surface is intact.
• C-terminal regulatory domain (CTD) carries nuclear import and export signals and dense sites for post-translational modification, including phosphorylation, acetylation, methylation and ubiquitination. It tunes stability, localisation and DNA-binding affinity.

An important consequence of tetramerisation is dominant-negative behaviour. Because mutant and wild-type monomers can co-assemble, a single mutant allele can poison mixed tetramers, which is why heterozygous TP53 mutations often produce a stronger loss of function than simple gene dosage would predict.

The p53 signalling pathway

The pathway begins with damage detection. Double-strand breaks activate ATM; replication stress and single-strand damage activate ATR. Both kinases, together with CHK1 and CHK2, phosphorylate p53 within its N-terminal region — Ser15 and Ser20 are the classical sites — and phosphorylation there disrupts MDM2 binding. p53 consequently escapes degradation, accumulates in the nucleus, and begins transactivating targets.

Which programme runs depends on context: the severity and duration of the damage, the cell type, and which co-factors are present. Moderate, repairable damage favours transient arrest via p21, giving repair machinery time to act. Severe or persistent damage favours apoptosis through BAX, PUMA and NOXA. Chronic stress in some cell types drives senescence, a permanent withdrawal from the cycle.

One point in older summaries needs correcting: p53 is not a driver of normal proliferation. In unstressed cells it is deliberately kept at low levels by continuous MDM2-mediated turnover, and its activation is fundamentally antiproliferative. Where p53 loss appears to accelerate growth, that reflects removal of a brake rather than loss of an accelerator.

Regulation by MDM2 and beyond

MDM2 is the dominant negative regulator, and it acts in two ways at once. It binds the N-terminal transactivation domain, physically blocking co-activator recruitment, and it functions as an E3 ubiquitin ligase, tagging p53 for proteasomal destruction. The result is a protein with a half-life measured in minutes under normal conditions.

The arrangement is a negative feedback loop, because MDM2 is itself a p53 target gene. Rising p53 drives MDM2 expression, which then degrades p53 — self-limiting the response and allowing the system to reset once damage is resolved. MDMX (MDM4) acts as a related repressor, primarily inhibiting transactivation rather than promoting degradation.

Additional layers of control

• ATM and ATR transduce damage signals into the phosphorylation events that break the p53–MDM2 interaction.
• p14ARF, expressed in response to oncogenic signalling such as deregulated MYC or RAS, sequesters MDM2 in the nucleolus and thereby stabilises p53. This is the route by which oncogene activation itself triggers a p53 response.
• Post-translational modifications beyond phosphorylation — acetylation by p300/CBP, methylation, sumoylation — modulate stability, co-factor recruitment and promoter selectivity.
• Ribosomal and metabolic stress also converge on the MDM2 axis, so p53 responds to more than genotoxic insult alone.

p53 target genes

p53 regulates hundreds of genes, but a small set accounts for most of its canonical output. Grouping them by the programme they serve makes the pathway easier to interpret experimentally.

Two clarifications are worth making, because both are commonly misstated. PUMA is a pro-apoptotic BH3-only protein, not a DNA repair factor — it belongs in the apoptosis group only. And p16INK4a is not a p53 target gene: encoded by CDKN2A, it operates in the parallel RB pathway and is regulated independently of p53. p53-driven senescence is mediated largely through sustained p21 expression. The two tumour suppressor pathways converge on cell cycle arrest but are distinct, and conflating them obscures why tumours frequently disable both.

Mutations and cancer

TP53 is altered in roughly half of all human cancers, with particularly high frequencies in ovarian, oesophageal, colorectal, head and neck, and lung squamous carcinomas. What distinguishes it from most tumour suppressors is the type of alteration.

Classical tumour suppressors are typically inactivated by truncation or deletion — the protein disappears. TP53 instead accumulates missense mutations, overwhelmingly clustered in the DNA-binding domain, at a handful of recurrent codons including 175, 245, 248, 249, 273 and 282. The full-length protein is still made; it simply cannot engage its response elements.

Consequences of missense mutation

• Loss of function. Mutant p53 cannot transactivate p21, PUMA or BAX, so arrest and apoptosis fail.
• Dominant-negative activity. Because the protein is tetrameric, mutant subunits co-assemble with wild-type subunits and inactivate mixed tetramers, so one mutant allele can suppress the remaining normal one.
• Gain of function. Certain mutants acquire activities the wild-type protein never had, interacting with other transcription factors and with p63 and p73 to promote invasion, metastasis and chemoresistance. This is why some TP53 mutations carry worse prognosis than outright deletion.
• Protein accumulation. Many mutants escape MDM2-mediated degradation and build up to high levels. A strongly p53-positive tumour by immunohistochemistry therefore often indicates mutation, not a functioning pathway — abundance is not activity.

Germline TP53 mutation causes Li-Fraumeni syndrome, with markedly elevated lifetime risk of sarcoma, breast cancer, brain tumours and adrenocortical carcinoma. p53 function can also be lost without mutating TP53 at all: MDM2 amplification, CDKN2A deletion removing p14ARF, or expression of viral oncoproteins such as HPV E6, which directs p53 for degradation.

Therapeutic approaches

p53 has proved a difficult target, for a structural reason: restoring a lost function is harder than blocking an active one. Several strategies are nonetheless in development.

MDM2 inhibitors are the most advanced concept. Nutlins and their successors occupy the p53-binding pocket on MDM2, releasing wild-type p53 in tumours that retain it. They are only rational where TP53 is intact, and haematological toxicity has been the recurring obstacle.

Mutant p53 reactivators aim to restore folding and DNA binding to specific mutants. Compounds in this class have entered trials, particularly for the Y220C mutant, which creates a druggable surface cavity absent from wild-type protein.

Synthetic lethality takes the opposite approach: rather than repairing p53, exploit the vulnerabilities its loss creates. p53-deficient cells depend more heavily on remaining checkpoints, which motivates combining DNA-damaging agents with WEE1, CHK1 or ATR inhibitors. Note that none of the above is established standard care, and this article is not clinical guidance.

How p53 is measured

Quantifying p53 requires deciding whether the question concerns abundance, modification state, or transcriptional output — and these can diverge sharply, especially in mutant contexts.

Methods

• Sandwich ELISA quantifies total or phospho-specific p53 in lysates, serum and plasma, giving a numerical result suited to comparing conditions or timepoints.
• Western blotting resolves p53 by molecular weight and, with phospho-specific antibodies, distinguishes modification states. It also reveals truncated products from nonsense mutations.
• Immunohistochemistry localises p53 within tissue. Strong diffuse nuclear staining is used clinically as a surrogate for missense mutation, while complete absence suggests a truncating one.
• Sequencing is the only way to identify which mutation is present, and increasingly the decisive assay given how much mutation identity affects behaviour.

Interpreting the result

The critical caveat is that p53 protein level is a poor proxy for p53 function. Mutant p53 frequently accumulates precisely because it evades MDM2-mediated turnover, so high p53 can indicate a dead pathway. Measuring a downstream target alongside it resolves the ambiguity: p21 is the most informative single readout of p53 transcriptional activity, and low p21 with high p53 is the signature of a non-functional pathway. Pairing p53 with p21 and an apoptotic effector such as PUMA or BAX gives a far more interpretable picture than p53 alone.

Frequently asked questions